Taysha Gene Therapies Inc (TSHA) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Taysha Gene Therapies Inc

NASDAQ | TSHA

1.24

USD

+0.06 (+5.08%)

AT CLOSE (AS OF Apr 17, 2025)

$254M

MARKET CAP

P/E Ratio

-0.36

EPS

$4.3

52 Week High

$1.1

52 Week Low

LIFE SCIENCES

Sector

TSHA Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

TSHA Technicals

Tags:

TSHA Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$8.3M
Total Revenue	$8.3M
Cost Of Revenue	-
Costof Goods And Services Sold	-
Operating Income	-$91M
Selling General And Administrative	$29M
Research And Development	$66M
Operating Expenses	$100M
Investment Income Net	-
Net Interest Income	$6.8M
Interest Income	$6.9M
Interest Expense	$102K
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$1.2M
Income Before Tax	-$89M
Income Tax Expense	-$89M
Interest And Debt Expense	-
Net Income From Continuing Operations	-$89M
Comprehensive Income Net Of Tax	-
Ebit	-$89M
Ebitda	-$88M
Net Income	-$89M

Revenue & Profitability

Earnings Performance

TSHA Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2024)

Field	Value (USD)
Total Assets	$160M
Total Current Assets	$142M
Cash And Cash Equivalents At Carrying Value	$139M
Cash And Short Term Investments	$139M
Inventory	-
Current Net Receivables	-
Total Non Current Assets	$18M
Property Plant Equipment	-
Accumulated Depreciation Amortization Ppe	-
Intangible Assets	-
Intangible Assets Excluding Goodwill	-
Goodwill	-
Investments	-
Long Term Investments	-
Short Term Investments	-
Other Current Assets	$3.1M
Other Non Current Assets	-
Total Liabilities	$89M
Total Current Liabilities	$26M
Current Accounts Payable	-
Deferred Revenue	-
Current Debt	-
Short Term Debt	-
Total Non Current Liabilities	$63M
Capital Lease Obligations	$19M
Long Term Debt	$44M
Current Long Term Debt	-
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$17M
Other Current Liabilities	$13M
Other Non Current Liabilities	$1.3M
Total Shareholder Equity	$72M
Treasury Stock	-
Retained Earnings	-$602M
Common Stock	$2K
Common Stock Shares Outstanding	$250M

yearly Cash Flow (As of Dec 31, 2024)

Field	Value (USD)
Operating Cashflow	-$81M
Payments For Operating Activities	-
Proceeds From Operating Activities	-
Change In Operating Liabilities	-
Change In Operating Assets	-
Depreciation Depletion And Amortization	$1.2M
Capital Expenditures	$374K
Change In Receivables	-
Change In Inventory	-
Profit Loss	-
Cashflow From Investment	-
Cashflow From Financing	$77M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	-
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$89M

yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$8.3M
Total Revenue	$8.3M
Cost Of Revenue	-
Costof Goods And Services Sold	-
Operating Income	-$91M
Selling General And Administrative	$29M
Research And Development	$66M
Operating Expenses	$100M
Investment Income Net	-
Net Interest Income	$6.8M
Interest Income	$6.9M
Interest Expense	$102K
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$1.2M
Income Before Tax	-$89M
Income Tax Expense	-$89M
Interest And Debt Expense	-
Net Income From Continuing Operations	-$89M
Comprehensive Income Net Of Tax	-
Ebit	-$89M
Ebitda	-$88M
Net Income	-$89M

TSHA News

TSHA Profile

Taysha Gene Therapies Inc Profile

Sector: LIFE SCIENCES

Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.00	9.68%	-	409,386,220
STSS	$0.03	20.75%	$522.68K	391,799,240
NVDA	$101.49	-2.87%	$2.48T	292,517,465
HTZ	$8.24	44.31%	$2.54B	266,908,117
FMTO	$0.02	-35.81%	$2.41M	198,396,141

Symbol	Price	Change %	Market Cap	Volume
LLY	$839.96	14.30%	$754.27B	10,853,385
PG	$170.63	2.55%	$400.10B	7,227,061
JNJ	$157.47	2.31%	$379.48B	10,981,067
ABBV	$172.99	0.76%	$306.02B	8,998,056
NVO	$58.08	-7.63%	$282.79B	32,220,629

Symbol	Price	Change %	Market Cap	Volume
MSGM	$2.75	145.54%	$8.75M	36,058,545
SXTC	$2.16	118.42%	$29.73M	51,508,885
ADGM	$1.78	92.81%	$54.65M	114,733,769
PNBK	$3.28	73.55%	$13.04M	1,511,087
RTC	$0.37	72.09%	$10.86M	187,018,434

Symbol	Price	Change %	Market Cap	Volume
JEWL	$0.00	-90.83%	$2.78M	470,134
LXEH	$6.84	-70.25%	$26.82M	1,373,607
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
MMV	$0.48	-51.02%	$11.90M	1,568,644

Quick Links

TSHA $1.24 (+5.08%) Quote details